Protagonist Therapeutics, Inc. (PTGX)

Market Cap	2.72B
Revenue (ttm)	207.80M
Net Income (ttm)	56.19M
Shares Out	61.98M
EPS (ttm)	0.86
PE Ratio	50.92
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,100,694
Open	41.86
Previous Close	43.09
Day's Range	41.72 - 44.30
52-Week Range	24.22 - 60.60
Beta	2.64
Analysts	Strong Buy
Price Target	66.50 (+51.41%)
Earnings Date	May 6, 2025

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 126
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX
• Website: https://www.protagonist-inc.com

Analyst Forecast

According to 8 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $66.5, which is an increase of 51.41% from the latest price.

Price Target

$66.5

(51.41% upside)

Analyst Consensus: Strong Buy